SPARCL1 Antibody

What is SPARCL1 and why is it significant in research?

SPARCL1 is a member of the SPARC family of extracellular glycoproteins that functions as an anti-adhesive protein. It's widely expressed in tissues including brain, heart, lung, muscle, and kidney, but notably absent in liver . Research significance stems from its downregulation in many epithelial cell-derived tumors, suggesting potential tumor suppressor functions . SPARCL1 has been implicated in regulating cellular adhesion, migration, and has demonstrated anti-angiogenic properties in colorectal carcinoma .

Why does SPARCL1 show discrepancy between predicted and observed molecular weight?

While SPARCL1 has a predicted molecular weight of approximately 75 kDa based on amino acid sequence, it typically migrates at 130-140 kDa on SDS-PAGE gels . This discrepancy is attributed to two possible mechanisms: (1) post-translational modifications, particularly extensive glycosylation, combined with the protein's high acidity, or (2) disulfide-linked homodimerization . Researchers should be aware of this characteristic when interpreting Western blot results, as the observed band will be significantly higher than the calculated molecular weight.

How does SPARCL1 expression differ between species and tissues?

Species- and organ-dependent expression patterns have been documented for SPARCL1:

This differential expression pattern suggests that SPARCL1 functions may not be identical between humans and mice, which has important implications for translational research using mouse models .

What criteria should be used when selecting a SPARCL1 antibody for specific applications?

When selecting a SPARCL1 antibody, consider:

• Application compatibility: Verify the antibody has been validated for your intended application (WB, IHC, IF, IP, or Flow Cytometry)

• Species reactivity: Confirm reactivity with your target species; note that cross-reactivity between human and mouse SPARCL1 varies between antibodies

• Epitope location: For detecting specific domains or fragments of SPARCL1, choose antibodies targeting relevant regions

• Validation data: Review the manufacturer's validation data for your specific application and tissue type

• Isotype and format: Consider whether polyclonal or monoclonal antibodies are more suitable for your application; polyclonals may offer higher sensitivity while monoclonals provide better specificity

How should SPARCL1 antibodies be validated before experimental use?

Proper validation should include:

• Positive and negative controls: Use tissues known to express (brain, lung) or not express (liver) SPARCL1

• Antibody specificity: Confirm through Western blot that the antibody detects the expected 130-140 kDa band

• Knockdown verification: If available, use SPARCL1 knockdown or knockout samples to confirm antibody specificity

• Blocking peptide competition: Test if pre-incubation with the immunizing peptide blocks antibody binding

• Cross-validation: Compare results with a second antibody targeting a different epitope of SPARCL1

What are the optimal conditions for detecting SPARCL1 by Western blot?

For optimal Western blot detection of SPARCL1:

• Sample preparation: Extract protein from tissues with high SPARCL1 expression (brain, heart, lung) using RIPA buffer with protease inhibitors

• Gel selection: Use 8-10% SDS-PAGE gels to properly resolve the 130-140 kDa SPARCL1 protein

• Transfer conditions: Transfer to PVDF membrane at 100V for 90 minutes in cold conditions

• Blocking: Block with 5% non-fat dry milk in TBST as verified in protocols

• Antibody dilution: Use recommended dilution ranges (typically 1:500-1:2000) and optimize empirically

• Positive control: Include human lung tissue lysate as a positive control

• Expected results: Look for a specific band at approximately 130 kDa

What are the recommended protocols for SPARCL1 immunohistochemistry?

For successful SPARCL1 immunohistochemistry:

• Fixation: Use 10% neutral buffered formalin for tissue fixation

• Antigen retrieval: Perform heat-induced epitope retrieval using either TE buffer (pH 9.0) or citrate buffer (pH 6.0)

• Primary antibody incubation: Apply at recommended dilution (1:50-1:500) and incubate either overnight at 4°C or for 15 minutes at room temperature depending on the antibody

• Detection system: Use appropriate HRP-DAB detection systems (e.g., Anti-Goat HRP-DAB Cell & Tissue Staining Kit)

• Positive control tissues: Human brain (cerebral cortex), tonsil tissue

• Negative control tissue: Human liver

• Expected results: Cytoplasmic staining in neurons for brain tissue

How should researchers design experiments to study SPARCL1 in cancer progression?

When studying SPARCL1 in cancer progression:

• Baseline expression: Establish baseline SPARCL1 expression in healthy tissues corresponding to your cancer model

• Matched samples: Use matched normal-tumor pairs from the same patient when possible to control for individual variation

• Cancer stage correlation: Analyze SPARCL1 expression across different cancer stages to identify stage-specific changes

• Cellular localization: Determine if SPARCL1 localization (not just expression level) changes during cancer progression

• Microenvironment considerations: Assess SPARCL1 expression in both tumor cells and the surrounding stroma, particularly endothelial cells

• Correlation with outcomes: Correlate SPARCL1 expression with clinical parameters and patient outcomes

• Functional validation: Perform gain/loss of function studies in appropriate cell lines to confirm causal relationships

What controls should be included when analyzing SPARCL1 expression in tissue samples?

Essential controls include:

• Positive tissue controls: Include tissues known to express high levels of SPARCL1 (brain, lung)

• Negative tissue controls: Include liver tissue, known to have minimal SPARCL1 expression

• Isotype controls: Include appropriate isotype antibody controls to assess non-specific binding

• Technical controls: Process serial sections without primary antibody

• Quantification controls: Include reference proteins of known concentration to enable accurate quantification

• Cell-type specific markers: Include markers for specific cell types (neurons, endothelial cells) to correlate SPARCL1 expression with particular cellular populations

How can researchers accurately distinguish between different SPARCL1 isoforms or fragments?

To differentiate SPARCL1 isoforms:

• Domain-specific antibodies: Use antibodies targeting different domains of SPARCL1 (N-terminal, follistatin-like, kazal-like, or calcium-binding domains)

• Size discrimination: Use gradient gels that can resolve the full-length protein (~130 kDa) from reported fragments (55 kDa C-terminal fragment in mouse kidney, 25 kDa fragment in human liver tumors)

• Mass spectrometry validation: Confirm protein identity and specific isoforms through mass spectrometric analysis

• RNA-level analysis: Complement protein analysis with RT-PCR or RNA-seq to identify alternatively spliced transcripts

• Recombinant protein standards: Include purified recombinant full-length and truncated SPARCL1 as size references

• 2D gel electrophoresis: Separate isoforms based on both molecular weight and isoelectric point

What approaches are recommended for studying SPARCL1 in the context of viral pneumonia?

Based on recent research showing SPARCL1's role in viral pneumonia:

• Temporal expression analysis: Monitor SPARCL1 expression at multiple timepoints post-infection (acute phase through recovery)

• Compartment-specific sampling: Analyze both bronchoalveolar lavage fluid (BALF) and serum to track local versus systemic SPARCL1 levels

• Cell-type resolution: Use flow cytometry and immunohistochemistry to identify specific cell populations expressing SPARCL1, particularly focusing on endothelial cells

• Functional studies: Consider using genetic models with endothelial-specific SPARCL1 overexpression or knockdown to study mechanistic roles

• Cytokine correlation: Correlate SPARCL1 levels with pro-inflammatory (TNF, IL-1β, IL-6, IFN-γ) and anti-inflammatory (IL-4, IL-10) cytokines

• Recovery metrics: Track physiological parameters like weight recovery, oxygen saturation, and survival probability alongside SPARCL1 expression

How can contradictory findings about SPARCL1 function between different models be reconciled?

To address contradictory findings:

• Species-specific differences: Consider that human and mouse SPARCL1 show different expression patterns and may have distinct functions

• Context-dependent roles: SPARCL1 may function differently depending on the tissue microenvironment; for example, it promotes synapse formation in neurons but inhibits angiogenesis in tumors

• Interaction partners: Analyze potential binding partners that may modify SPARCL1 function in different contexts

• Post-translational modifications: Investigate tissue-specific modifications that could alter protein function

• Functional redundancy: Consider compensatory mechanisms involving related proteins like SPARC, which can have opposing effects to SPARCL1 in some contexts

• Experimental system limitations: Evaluate differences between in vitro and in vivo studies, as well as acute versus chronic models

How can researchers address weak or absent SPARCL1 signal in Western blots?

For improving SPARCL1 detection:

• Protein extraction optimization: Use extraction buffers containing both non-ionic detergents and chaotropic agents to effectively solubilize this extracellular matrix protein

• Sample enrichment: Consider immunoprecipitation to concentrate SPARCL1 before Western blotting

• Transfer efficiency: Increase transfer time for this high molecular weight protein (130-140 kDa)

• Antibody selection: Try multiple antibodies targeting different epitopes, as some regions may be masked by glycosylation or protein folding

• Sensitivity enhancement: Use high-sensitivity chemiluminescent substrates or fluorescent secondary antibodies

• Tissue selection: Ensure you're using appropriate positive control tissues (brain, lung) rather than tissues with low expression (liver)

A 6.2. What are potential explanations for discrepancies in SPARCL1 detection between different antibodies?

Discrepancies may arise from:

• Epitope accessibility: Different antibodies target distinct epitopes that may be differentially accessible due to protein folding, post-translational modifications, or protein-protein interactions

• Isoform specificity: Some antibodies may preferentially detect specific isoforms or fragments of SPARCL1

• Cross-reactivity: Antibodies may exhibit different levels of cross-reactivity with related proteins like SPARC

• Technical variables: Differences in antibody affinity, optimal working conditions, or application-specific performance

• Species specificity: While some antibodies work across species, others may be species-specific due to sequence differences between human and mouse SPARCL1